Shanghai Fosun Pharmaceutical Group Co Ltd (600196) - Net Assets

Latest as of March 2026: CN¥63.67 Billion CNY ≈ $9.32 Billion USD

Based on the latest financial reports, Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has net assets worth CN¥63.67 Billion CNY (≈ $9.32 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥122.97 Billion ≈ $17.99 Billion USD) and total liabilities (CN¥59.30 Billion ≈ $8.68 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shanghai Fosun Pharmaceutical Group Co L PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥63.67 Billion
% of Total Assets	51.78%
Annual Growth Rate	29.69%
5-Year Change	29.18%
10-Year Change	147.5%
Growth Volatility	73.57

Shanghai Fosun Pharmaceutical Group Co Ltd - Net Assets Trend (1995–2025)

This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shanghai Fosun Pharmaceutical Group Co L market capitalisation.

Annual Net Assets for Shanghai Fosun Pharmaceutical Group Co Ltd (1995–2025)

The table below shows the annual net assets of Shanghai Fosun Pharmaceutical Group Co Ltd from 1995 to 2025. Also explore 600196 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	CN¥62.49 Billion ≈ $9.14 Billion	+4.27%
2024-12-31	CN¥59.93 Billion ≈ $8.77 Billion	+5.86%
2023-12-31	CN¥56.62 Billion ≈ $8.28 Billion	+4.63%
2022-12-31	CN¥54.11 Billion ≈ $7.92 Billion	+11.85%
2021-12-31	CN¥48.38 Billion ≈ $7.08 Billion	+5.20%
2020-12-31	CN¥45.98 Billion ≈ $6.73 Billion	+17.29%
2019-12-31	CN¥39.20 Billion ≈ $5.74 Billion	+16.70%
2018-12-31	CN¥33.59 Billion ≈ $4.92 Billion	+12.95%
2017-12-31	CN¥29.74 Billion ≈ $4.35 Billion	+17.79%
2016-12-31	CN¥25.25 Billion ≈ $3.69 Billion	+22.16%
2015-12-31	CN¥20.67 Billion ≈ $3.02 Billion	+8.20%
2014-12-31	CN¥19.10 Billion ≈ $2.80 Billion	+8.14%
2013-12-31	CN¥17.66 Billion ≈ $2.58 Billion	+15.42%
2012-12-31	CN¥15.30 Billion ≈ $2.24 Billion	+34.60%
2011-12-31	CN¥11.37 Billion ≈ $1.66 Billion	+21.05%
2010-12-31	CN¥9.39 Billion ≈ $1.37 Billion	+35.12%
2009-12-31	CN¥6.95 Billion ≈ $1.02 Billion	+56.37%
2008-12-31	CN¥4.45 Billion ≈ $650.58 Million	+3.00%
2007-12-31	CN¥4.32 Billion ≈ $631.62 Million	+18.30%
2006-12-31	CN¥3.65 Billion ≈ $533.90 Million	+26.90%
2005-12-31	CN¥2.88 Billion ≈ $420.71 Million	+2.18%
2004-12-31	CN¥2.81 Billion ≈ $411.75 Million	+39.51%
2003-12-31	CN¥2.02 Billion ≈ $295.14 Million	+20.53%
2002-12-31	CN¥1.67 Billion ≈ $244.87 Million	+26.52%
2001-12-31	CN¥1.32 Billion ≈ $193.54 Million	+8.55%
2000-12-31	CN¥1.22 Billion ≈ $178.30 Million	+85.44%
1999-12-31	CN¥657.08 Million ≈ $96.15 Million	+23.80%
1998-12-31	CN¥530.77 Million ≈ $77.67 Million	+300.05%
1997-12-31	CN¥132.68 Million ≈ $19.41 Million	+314.91%
1996-12-31	CN¥31.98 Million ≈ $4.68 Million	+24.91%
1995-12-31	CN¥25.60 Million ≈ $3.75 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Fosun Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1010853.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥29.80 Billion	61.14%
Common Stock	CN¥2.67 Billion	5.48%
Other Comprehensive Income	CN¥714.03 Million	1.46%
Other Components	CN¥15.55 Billion	31.91%
Total Equity	CN¥48.74 Billion	100.00%

Shanghai Fosun Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Fosun Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company	Market Cap
Kesko Oyj HE:KESKOB	$7.18 Billion
Noble Corporation plc NYSE:NE	$7.19 Billion
3Peak Inc SHG:688536	$7.19 Billion
Osisko Gold Ro TO:OR	$7.19 Billion
HealthEquity Inc NASDAQ:HQY	$7.17 Billion
Hyundai Autoever Corp KO:307950	$7.15 Billion
Far East Smarter Energy Co Ltd SHG:600869	$7.15 Billion
HITACHI CONSTR.MACH.ADR/2 F:HCMA	$7.15 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Fosun Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 47,261,107,000 to 48,741,507,000, a change of 1,480,400,000 (3.1%).
Net income of 3,370,562,000 contributed positively to equity growth.
Dividend payments of 844,702,310 reduced retained earnings.
Share repurchases of 411,788,500 reduced equity.
Other comprehensive income decreased equity by 792,007,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥3.37 Billion	+6.92%
Dividends Paid	CN¥844.70 Million	-1.73%
Share Repurchases	CN¥411.79 Million	-0.84%
Other Comprehensive Income	CN¥-792.01 Million	-1.62%
Other Changes	CN¥158.34 Million	+0.32%
Total Change	CN¥-	3.13%

Book Value vs Market Value Analysis

This analysis compares Shanghai Fosun Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.26x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 1588.80x to 1.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1995-12-31	CN¥0.01	CN¥23.13	x
1996-12-31	CN¥0.02	CN¥23.13	x
1997-12-31	CN¥0.06	CN¥23.13	x
1998-12-31	CN¥0.30	CN¥23.13	x
1999-12-31	CN¥0.34	CN¥23.13	x
2000-12-31	CN¥0.65	CN¥23.13	x
2001-12-31	CN¥0.72	CN¥23.13	x
2002-12-31	CN¥0.80	CN¥23.13	x
2003-12-31	CN¥0.97	CN¥23.13	x
2004-12-31	CN¥1.31	CN¥23.13	x
2005-12-31	CN¥1.36	CN¥23.13	x
2006-12-31	CN¥1.76	CN¥23.13	x
2007-12-31	CN¥2.10	CN¥23.13	x
2008-12-31	CN¥2.17	CN¥23.13	x
2009-12-31	CN¥3.49	CN¥23.13	x
2010-12-31	CN¥4.49	CN¥23.13	x
2011-12-31	CN¥5.11	CN¥23.13	x
2012-12-31	CN¥6.94	CN¥23.13	x
2013-12-31	CN¥6.81	CN¥23.13	x
2014-12-31	CN¥7.26	CN¥23.13	x
2015-12-31	CN¥7.83	CN¥23.13	x
2016-12-31	CN¥9.49	CN¥23.13	x
2017-12-31	CN¥10.29	CN¥23.13	x
2018-12-31	CN¥11.06	CN¥23.13	x
2019-12-31	CN¥12.44	CN¥23.13	x
2020-12-31	CN¥14.44	CN¥23.13	x
2021-12-31	CN¥15.29	CN¥23.13	x
2022-12-31	CN¥17.10	CN¥23.13	x
2023-12-31	CN¥17.04	CN¥23.13	x
2024-12-31	CN¥17.74	CN¥23.13	x
2025-12-31	CN¥18.42	CN¥23.13	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Fosun Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.92%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.12%
• Asset Turnover: 0.34x
• Equity Multiplier: 2.47x
Recent ROE (6.92%) is below the historical average (13.49%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1995	23.35%	9.25%	0.61x	4.17x	CN¥3.42 Million
1996	19.95%	6.88%	0.83x	3.48x	CN¥3.18 Million
1997	39.35%	20.82%	0.66x	2.85x	CN¥29.56 Million
1998	12.28%	18.72%	0.53x	1.25x	CN¥11.81 Million
1999	15.25%	20.83%	0.52x	1.42x	CN¥31.71 Million
2000	11.22%	22.67%	0.36x	1.37x	CN¥13.96 Million
2001	10.72%	18.62%	0.33x	1.75x	CN¥9.12 Million
2002	10.44%	14.27%	0.33x	2.23x	CN¥6.26 Million
2003	15.51%	12.24%	0.51x	2.48x	CN¥93.60 Million
2004	9.35%	8.94%	0.47x	2.24x	CN¥-15.08 Million
2005	6.65%	5.32%	0.53x	2.37x	CN¥-80.06 Million
2006	8.39%	6.35%	0.62x	2.15x	CN¥-49.86 Million
2007	16.16%	16.94%	0.50x	1.92x	CN¥238.55 Million
2008	17.23%	18.31%	0.50x	1.88x	CN¥289.97 Million
2009	38.57%	64.88%	0.33x	1.78x	CN¥1.85 Billion
2010	10.25%	18.96%	0.27x	2.00x	CN¥21.35 Million
2011	11.93%	17.97%	0.29x	2.28x	CN¥188.42 Million
2012	11.53%	21.30%	0.29x	1.88x	CN¥208.04 Million
2013	10.32%	15.83%	0.34x	1.92x	CN¥49.34 Million
2014	12.67%	17.57%	0.34x	2.12x	CN¥445.38 Million
2015	13.53%	19.51%	0.33x	2.10x	CN¥641.94 Million
2016	12.64%	19.18%	0.33x	1.97x	CN¥586.82 Million
2017	12.34%	16.86%	0.30x	2.45x	CN¥591.81 Million
2018	9.68%	10.87%	0.35x	2.52x	CN¥-89.85 Million
2019	10.42%	11.62%	0.38x	2.39x	CN¥132.81 Million
2020	9.90%	12.09%	0.36x	2.26x	CN¥-36.74 Million
2021	12.07%	12.12%	0.42x	2.38x	CN¥809.52 Million
2022	8.37%	8.49%	0.41x	2.40x	CN¥-727.44 Million
2023	5.22%	5.76%	0.36x	2.48x	CN¥-2.18 Billion
2024	5.86%	6.74%	0.35x	2.49x	CN¥-1.96 Billion
2025	6.92%	8.12%	0.34x	2.47x	CN¥-1.50 Billion

Industry Comparison

This section compares Shanghai Fosun Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,877,324,223
Average return on equity (ROE) among peers: 8.08%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shanghai Fosun Pharmaceutical Group Co Ltd (600196)	CN¥63.67 Billion	23.35%	0.93x	$7.17 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.78 Billion	1.33%	4.40x	$589.07 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.56 Billion	7.90%	1.45x	$422.95 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$2.46 Billion	15.95%	0.27x	$4.31 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.17 Billion	10.59%	0.88x	$2.30 Billion
Wedge Industrial Co Ltd (000534)	$1.41 Billion	5.42%	0.68x	$1.73 Billion
Yunnan Baiyao Group Co Ltd (000538)	$32.60 Million	12.25%	0.82x	$13.40 Billion
Hainan Haiyao Co Ltd (000566)	$2.54 Billion	7.70%	0.92x	$945.43 Million
Tus Pharmaceutical Group Co Ltd (000590)	$380.02 Million	7.98%	0.67x	$320.64 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$3.92 Billion	4.44%	2.20x	$1.01 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$23.53 Billion	7.26%	0.16x	$3.11 Billion

About Shanghai Fosun Pharmaceutical Group Co Ltd

SHG:600196 China Drug Manufacturers - Specialty & Generic

Market Cap

$7.17 Billion

CN¥49.00 Billion CNY

Market Cap Rank

#2855 Global

#353 in China

Share Price

CN¥23.13

Change (1 day)

+0.35%

52-Week Range

CN¥21.21 - CN¥30.34

All Time High

CN¥85.06